Tickernomics

10y

Historical Returns*:

SPY

27.80%

CDTX

43.33%

SPY

32.66%

-3.25%

CDTX

SPY

108.59%

-63.26%

CDTX

SPY

302.52%

CDTX

0.00%

*Assumes dividends reinvested

Market Stats:

Market Capitalization($MM)

Enterprise Value($MM)

Daily Volume(MM)

153.00

28.92

0.05

Valuation Metrics:

Price/Earnings Ratio

Price/Sales Ratio

Price/Book Value

FCF Yield(%)

Dividend Yield(%)

EV/EBITDA

-1.24

4.30

1.32

-326.04

0.00

-0.20

Profitability Stats:

Operating Margin %(ttm)

Gross Profit %(ttm)

EBITDA Margin %(ttm)

-5759.60

81.13

-1507.61

Shareholder Value Creation:

Cost of Capital %(est)

ROIC %(ttm)

ROCE %(ttm)

Beta

8.0736

-2108.67

-4964.48

1.02

Other Earnings and Cash Flow Stats:

Cidara Therapeutics Inc. ( CDTX ) Net Income TTM ($MM) is -123.13

Cidara Therapeutics Inc. ( CDTX ) Operating Income TTM ($MM) is -130.14

Cidara Therapeutics Inc. ( CDTX ) Owners' Earnings Annual ($MM) is 0.00

Cidara Therapeutics Inc. ( CDTX ) Current Price to Owners' Earnings ratio is 0.00

Cidara Therapeutics Inc. ( CDTX ) EBITDA TTM ($MM) is -129.95

Cidara Therapeutics Inc. ( CDTX ) EBITDA Margin is -1507.61%

Capital Allocation:

Cidara Therapeutics Inc. ( CDTX ) has paid 0.00 dividends per share and bought back -2.015739 million shares in the past 12 months

Cidara Therapeutics Inc. ( CDTX ) has reduced its debt by 0.97 million USD in the last 12 months

Capital Structure:

Cidara Therapeutics Inc. ( CDTX ) Interest-bearing Debt ($MM) as of last quarter is 3

Cidara Therapeutics Inc. ( CDTX ) Annual Working Capital Investments ($MM) are 15

Cidara Therapeutics Inc. ( CDTX ) Book Value ($MM) as of last quarter is 115

Cidara Therapeutics Inc. ( CDTX ) Debt/Capital as of last quarter is 2%

Other Balance Sheet Stats:

Cidara Therapeutics Inc. ( CDTX ) has 127 million in cash on hand as of last quarter

Cidara Therapeutics Inc. ( CDTX ) has 44 million of liabilities due within 12 months, and long term debt 0 as of last quarter

Cidara Therapeutics Inc. ( CDTX ) has 6 common shares outstanding as of last quarter

Cidara Therapeutics Inc. ( CDTX ) has 0 million USD of preferred stock value

Academic Scores:

Cidara Therapeutics Inc. ( CDTX ) Altman Z-Score is -4.84 as of last quarter

Cidara Therapeutics Inc. ( CDTX ) Piotroski Score is 2.00 as of last quarter

Corporate Governance:

Cidara Therapeutics Inc. ( CDTX ) largest shareholder is Checkpoint Capital L.P. owning 182426 shares at 4.24 ($MM) value

Sandison Taylor(an insider) Sold 924 shares of Cidara Therapeutics Inc. ( CDTX ) for the amount of $10752.31 on 2024-09-11

4.73% of Cidara Therapeutics Inc. ( CDTX ) is held by insiders, and 51.86% is held by institutions

Cidara Therapeutics Inc. ( CDTX ) went public on 2015-04-15

About Cidara Therapeutics Inc. ( CDTX ) :

Cidara Therapeutics, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of long-acting anti-infectives for the treatment and prevention of infectious diseases and oncology in the United States. The company's lead product candidate is rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates. It also advances its Cloudbreak platform to develop conjugates for the prevention and treatment of influenza and other viral infections, such as RSV, HIV, and the SARS-CoV-2 strains causing COVID-19. The company was formerly known as K2 Therapeutics, Inc. and changed its name to Cidara Therapeutics, Inc. in July 2014. The company was incorporated in 2012 and is based in San Diego, California.

DISCLAIMER

This web site and its creators are not certified financial advisors. All opinions/suggestions expressed on this website should not be treated as specific inducement to make a particular investment or follow a particular strategy, but only as an expression of an opinion.The Company doesn't warrant the information provided on the website for its completeness or accuracy, and it should not be relied upon as such. The Company is not under any obligation to update or correct any information provided on this website.The content of this website is published in the United States of America and persons who access it agree to do so in accordance with applicable U.S. law.Past performance is not indicative of future results. The Company doesn't guarantee any specific outcome or profit. You should be aware of the real risk of loss in following any strategy or investment discussed on this website.Strategies or investments discussed may fluctuate in price or value. Investors may get back less than invested. Investments or strategies mentioned on this website may not be suitable for you. This material does not take into account your particular investment objectives,financial situation or needs and is not intended as recommendations appropriate for you. You must make an independent decision regarding investments or strategies mentioned on this website. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser.